期刊文献+

尿脱落细胞吖啶橙染色阳性与膀胱移行细胞癌临床病理特征的关系 被引量:1

下载PDF
导出
摘要 目的探讨尿脱落细胞吖啶橙染色(AO-F)阳性与膀胱移行细胞癌(TCC)临床病理特征的关系。方法膀胱TCC患者400例,连续3 d收集晨尿,行AO-F检查,并对不同级别、直径及数目、位置、手术方式患者的AOF阳性率进行比较。结果 400例膀胱TCC患者AO-F总阳性率为77.0%,不同肿瘤分期、分级、直径、数目、手术方式者AO-F阳性率差异有统计学意义(P均<0.05)。肿瘤分期与AO-F阳性率之间呈正相关(P=0.002,r=0.962)。结论 AO-F阳性率与肿瘤临床分期有关。
出处 《山东医药》 CAS 2013年第38期84-85,共2页 Shandong Medical Journal
  • 相关文献

参考文献16

  • 1Liou LS. Urothelial cancer biomarkers for detection and surveil- lance [ J ]. Urology, 2006,67 ( 3 Suppl 1 ) :25-34.
  • 2黄世明,倪江雯,魏学斌,李青.膀胱癌的诊断[J].山东医药,2009,49(22):112-112. 被引量:3
  • 3艾衍凯,张天禹.尿液中膀胱癌早期无创诊断的研究进展[J].中国医药指南,2013,11(3):445-447. 被引量:2
  • 4Fernandez GJ, Garcia RJ, Escaf BS, et al. Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma [ J ]. Arch Esp Urol, 2002,55 ( 1 ) :41-49.
  • 5Dey P. Urinary markers of bladder carcinoma[ J]. Clin Cbim Ac- ta, 2004,340( 1-2 ) :57-65.
  • 6康绍叁,赵艳生,曹凤宏,李化永,尔雅娜,高伟兴,李晓强.尿survivin、NMP22及脱落细胞联合检测在膀胱移行细胞癌诊断中的应用[J].山东医药,2012,52(14):66-67. 被引量:7
  • 7Cai T, Mazzoli S, Meacci F, et al. Interleukin-6/10 ratio as a prog- nostic marker of recurrence in patients with intermediate risk urothe- lial bladder carcinoma[J]. J Urol, 2007,178(5) :1906-1911.
  • 8Siracusano S, Niceolini B, Knez R, et al. The simultaneous use of telomerasc, cytokeratin 20 and CD4 for bladder cancer detection in urine[J]. Eur Urol, 2005,47(3) :327-333.
  • 9Brown FM. Urine cytology. It is still the gold standard for screen- ing[ J]. Uml Clin North Am, 2000,27( 1 ) :25-37.
  • 10Wiener HG, Vooijs GP, Vant HB. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer [ J ]. Acta Cytol, 1993,37 ( 2 ) : 163-169.

二级参考文献40

  • 1王国民 缪廷杰 张元芳 熊汝成 周康 许迅辉.尿脱落细胞吖啶橙染色法诊断膀胱癌[J].临床泌尿外科杂志,1987,2(2):76-78.
  • 2吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2003:1965-2973.
  • 3Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5): 277-330.
  • 4Edwards BK,Ward E,Kohler BA,et al.Annual report to the nation on the status of cancer,1975-2006,featuring colorectal cancer trends and impact of interventions(risk factors,screening,and treatment) to reduce future rates[J].Cancer,2010,116(3): 544-573.
  • 5Jacobs BL,Lee CT, Montie JE.Bladder cancer.in 2010: how far have we come?[J].CA Cancer J Clin,2010,60(4): 244-272.
  • 6Cancer Facts and Figures,2004[M].Atlanta: American Cancer Society, Inc,2004.
  • 7那彦群,叶章群,孙光.中国泌尿外科疾病诊断治疗指南手册[S].北京:人民卫生出版社,2011:34-50.
  • 8Malkhasian KA,Petrov SV, Urianin M,et al.Use of fluoresent in situ hybridization in the cvtogenetic diagnosis of urinary bladder uroth- elial carcinoma[J].Vopr Onkol,2011,57(4): 462-469.
  • 9Xu C,Zeng Q,Hou J,Gao L,et al.Utility of a modality combining FISH and cytology in upper tract urothelial carcinoma detection in voided urine samples of Chinese patients[J].Urology,2011,77(3): 636-641.
  • 10Jia XY, Yu Q,Zhang ZH,Yang XF.Targeting bladder tumor cells in voided urine of Chinese patients with FITC-CSNRDARRC peptide ligand[J].Onco Targets Ther,2012,5: 85-90.

共引文献13

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部